Century Therapeutics has announced that it has acquired Empirica Therapeutics. Century Therapeutics said the acquisition will allow the company to develop its iPSC derived allogeneic cell therapies against glioblastoma (GBM).
Empirica Therapeutics has been developing treatments for GBM using a powerful integrative mult-omics platfom, combined with its unique patient-derived, therapy-adapted models of recurrent GBM. The company’s studies have led to the discovery and validation of novel brain tumour targets.
Recently, the Empirica research team published results which showed that their CAR-T therapy helped reduce the tumour burden and improved survival in mouse models.